Obesity and overweight are reaching global epidemic proportions affecting more than 1.1 billion individuals worldwide. Excess weight is associated with an increased mortality, chronic morbidity (including type 2 diabetes, arterial hypertension, cardiovascular diseases, and certain cancers), decreased quality of life, and considerable health care costs (1).

Antiobesity drugs work through different mechanisms either in the central nervous system (CNS) or in the peripheral tissues. These mechanisms include: 1) suppression of food intake in the CNS, 2) decreased gut absorption of nutrients, and 3) increased energy expenditure or oxidation of nutrients. The efficacy of antiobesity drugs should be evaluated by their ability to reduce fat stores (preferentially visceral adipose tissue), maintain weight loss, diminish obesity-related health risks, and thus decrease morbidity and mortality, and improve quality of life. An ideal antiobesity drug should be administered orally, devoid of major side effects, and distributed at affordable price. Treatment with antiobesity drugs can be considered in obese patients who failed to achieve a sufficient weight loss to a program of lifestyle change, diet, and physical activity. However, the drug treatment of obesity should be an integral part of the comprehensive obesity treatment program that includes diet, exercise, and cognitive behavioral intervention (2,3). Treatment of obesity should be individually tailored taking into account the degree and character of obesity, age, sex, and the presence of comorbidities (4). Drugs used for the treatment of obesity in the past were associated with serious side effects (psycho-stimulatory, depression, addiction, cardio-excitatory effects, pulmonary hypertension, and valve disease). Antiobesity agents that possess cardio-excitatory and psycho-stimulatory effects (e.g., phentermine, ephedrine, and caffeine mixture) have still been available for the short-term use in some countries (<3 months).

**SIBUTRAMINE AND ORLISTAT**

Currently, only two drugs, sibutramine and orlistat, are prescribed for long-term administration. The most important trial evaluating the long-term efficacy of sibutramine was the Sibutramine Trial of Obesity Reduction and Maintenance (STORM) in duration of 2 years (5), while the Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study assessing orlistat efficacy in preventing type 2 diabetes in obese subjects was carried out over a 4-year period (6). Meta-analysis of randomized trials revealed that sibutramine led to 4.2 kg and orlistat to 2.9 kg weight reduction in comparison with placebo (7). Four of the seven studies comparing sibutramine and orlistat monotherapy showed that sibutramine was significantly more efficacious for weight loss, and the remaining three studies showed equivalent effects (8). Modest weight loss (5–10%) in response to antiobesity drug treatment was associated with an improvement in lipid and glycemic profile. Sibutramine improved concentrations of HDL cholesterol and triglycerides, whereas orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and LDL cholesterol (7). Norris et al. (9) conducted a meta-analysis on the efficacy of orlistat and sibutramine in obese adults with type 2 diabetes and found only modest reductions of glycated hemoglobin (0.4% with orlistat, 0.7% with sibutramine). The improvement in lipid profile in response to sibutramine and orlistat is greater than can be expected from weight loss per se. A systemic review and a meta-analysis on attrition rate in trials with weight loss medications reported either similar total dropout rate for orlistat and sibutramine (10) or somewhat lower dropout rate on sibutramine (8).

The sibutramine treatment favorably affects inflammatory cytokines, serum hormonal levels (resistin, adiponectin), and the transport of leptin through the blood-brain barrier. Antiobesity effects and adverse events are related to the mechanisms of action of both drugs. Sibutramine selectively inhibits reuptake of serotonin, norepinephrine, and partly dopamine in the hypothalamus. This action results in an enhanced satiety and slightly increased thermogenesis (11). Orlistat reduces dietary fat absorption by inhibition of gastrointestinal and pancreatic lipase. The peripheral sympathomimetic activity of sibutramine leads to an increase in both systolic (sBP) and diastolic blood pressure (dBP) and pulse rate. However combined analysis of two placebo-controlled trials concluded that sibutramine treatment is unlikely to elicit a critical increase in blood pressure even in hypertensive patients with well-controlled hypertension. This is explained by the clonidine-like effect of sibutramine, which is mediated through activation of central α2-adrenoceptors (12). A recent meta-analysis of long-term changes in blood pressure following orlistat (12 trials including 5,540 patients) and sibutramine (6 trials including 1,495 patients) treatment in placebo-controlled trials of 12-months duration revealed a
modest decrease in both sBP (−1.9 mmHg) and dBP (−1.5 mmHg) in response to orlistat treatment, whereas sibutramine treatment led to a modest increase in sBP (+0.5 mmHg) and dBP (+1.7 mmHg) (13). It should be pointed out that the reduction of blood pressure in patients with type 2 diabetes after orlistat treatment was less pronounced and the increase in blood pressure after sibutramine was higher. A recent experience from the Sibutramine Cardiovascular Outcomes (SCOUT) trial clearly indicated that sibutramine administration should be strictly avoided in patients with a history of cardiovascular disease, including those with uncontrolled hypertension (14, 15).

Ten years of experiences with sibutramine and orlistat in the treatment of obesity and related conditions in both adults and adolescents were recently reviewed (16–18). In addition to obesity, the efficacy and safety of both drugs in the treatment of nonalcoholic fatty liver disease, polycystic ovary syndrome, and binge eating disorder were reported. Improvement in health-related quality of life was shown in sibutramine-treated patients who achieved moderate weight loss (19). Sibutramine treatment—induced weight loss is associated with improvement in eating attitudes as documented by increased dietary restraint and decreased dietary disinhibition and hunger scores (20). The weight loss with orlistat is not related to eating behavior attitudes but is associated with personality traits such as “order” and “deliberation” and thus, in contrast to sibutramine, is more demanding and requires greater adherence (21).

Orlistat inhibits gastrointestinal and pancreatic lipase and thus the weight loss and favorable metabolic effects are mainly achieved by 30% reduction in dietary fat absorption. Because of the insignificant intestinal absorption and subsequent low bioavailability of orlistat, both its anti-obesity effects and side effects (steatorrhea, oily spotting, fecal incontinence) are mediated via the gastrointestinal tract. The administration of orlistat is contraindicated in patients with malabsorption syndrome and cholestasis. Until now, no definite association between liver injury and orlistat administration has been established. Orlistat blocks the absorption of fat-soluble vitamins and β-carotene, and thus their substitution is recommended during the long-term administration of orlistat.

**IS TESOFENSINE THE SUCCESSOR OF SIBUTRAMINE?**—Tesofensine is a recently discovered norepinephrine-, dopamine-, and serotonin-reuptake inhibitor, which might have the potential to evoke a weight loss twice that of currently approved drugs (22). A considerable effect of tesofensine on appetite sensations and a moderate effect on energy expenditure at night can contribute to its strong weight-reducing effect (23). The observed weight loss was mainly because of the loss of fat mass and was accompanied by a significant decrease in anthropometric measures of abdominal obesity as the waist circumference and the sagittal abdominal diameter. Beneficial effects of tesofensine administration were demonstrated on the levels of total cholesterol, triglycerides, insulin, adiponectin, and hemoglobin A1c. The most frequently observed adverse events (nausea, dry mouth, constipation, and insomnia) are similar for tesofensine and sibutramine. Increases in pulse rate, but no significant increases in sBP and dBP, were observed after 24-weeks treatment with tesofensine in a dose of 0.25 or 0.50 mg. However, these findings on the efficacy and safety of tesofensine with regard to its potential adverse effects (cardiovascular and CNS) need confirmation in phase III trials conducted in larger cohorts of obese patients.

**IS CETILISTAT THE SUCCESSOR OF ORLISTAT?**—The efficacy and safety of cetilistat, a novel inhibitor of gastrointestinal lipases, was determined in both obese nondiabetic (24) and diabetic (25) patients. Similar weight reductions were observed in patients treated with cetilistat and orlistat (25). Weight reductions (from −3.3 kg to −4.3 kg) achieved by the treatment with different doses of cetilistat (60 mg t.i.d., 120 mg t.i.d., 240 mg t.i.d.) over a 12-week period were statistically significant compared with placebo (24, 25). The treatment with cetilistat resulted in significant reductions in total and LDL cholesterol levels in obese patients (24) and in an improved glycemic control in obese patients with diabetes (25). Cetilistat treatment was well tolerated and exhibited fewer side effects compared with orlistat. Significantly reduced frequency of gastrointestinal adverse events after cetilistat could be attributable to structural differences between the two molecules and their interaction with fat micelles in the intestine (25).

**LEPTIN: TREATMENT OF RELATIVE LEPTIN DEFICIENCY?**—Obesity, metabolic, neuroendocrine, and behavioral consequences of the rare congenital leptin deficiency in humans are efficiently reversed by the treatment with recombinant leptin (26). On the other hand, subjects with common obesity are hyperleptinemic compared with normal weight individuals and resistant to the central hypothalamic effects of endogenous leptin and less sensitive to exogenous leptin (27). However, some obese subjects who have recently lost weight exhibit a relative leptin deficiency and reduced concentrations of thyroid hormones that could be reversed by an administration of exogenous leptin (28). Further studies are needed to support the role of leptin administration for weight maintenance in subjects who develop relative leptin deficiency in response to calorie deficit.

**MELANOCORTIN-4 RECEPTOR AGONISTS**—In contrast to the rare congenital leptin deficiency, melanocortin-4 receptor (MC4R) mutations are the most common causes of monogenic obesity. MC4R deficiency is responsible for 0.5–2.5% of severe obesity. Two novel MC4R agonists were recently identified that were able in vitro to activate mutated human MC4R (29). However, clinical trials are required to confirm the efficiency and safety of these compounds in humans.

**LORCASERIN: A SAFE SUCCESSOR OF DEXFENFLURAMINE?**—Dexfenfluramine addressed serotoninergic hypothalamic appetite control mechanisms and led to body weight loss, increased adherence to a weight management program, and favorably affected cardiometabolic health risks in both obese nondiabetic (30) and diabetic (31) patients. However the mechanism of dexfenfluramine action—stimulation of serotonin release, inhibition of its reuptake, and direct stimulation of postsynaptic serotonin receptors—was also associated with serious side effects such as valve disease and pulmonary arterial hypertension (32, 33). In response to these observations, fenfluramine and dexfenfluramine were voluntarily withdrawn from the market in 1997 (33).
In order to avoid adverse peripheral side effects, a new selective serotonin agonist, lorcaserin, has recently been developed. Lorcaserin selectively activates 5-HT2C receptors, which are located primarily in the hypothalamus, thalamus, and limbic structures and are virtually absent in peripheral tissues. This way, unfavorable cardiovascular side-events are avoided (34). The administration of lorcaserin to obese subjects in both short-term (2 weeks) and long-term (1-year and 2-year) trials resulted in decreased body weight and waist circumference as well as in improved cardiometabolic risk profile and quality of life (35–37). At 1-year follow-up, significantly more patients lost 5% of their body weight in the lorcaserin group than in the placebo group (47.5 vs. 20.3%, P < 0.001), corresponding to an average weight loss of 5.8 ± 0.2 kg with lorcaserin and 2.2 ± 0.1 kg with placebo (37). No drug-related effects on heart valves, pulmonary artery pressure, or depression and suicidal ideation were recorded. Transient headache, nausea, and dizziness were the most frequently reported side-effects (35,37).

**DRUGS BLOCKING CANNABINOIDS AND DOPAMINERGIC RECEPTORS**

The blockade of cannabinoid CB1 receptors (with rimonabant or tavanabant) and dopaminergic D1/D5 receptors (with ecopipam) exerted favorable effects on body weight and cardiometabolic health risks (38–41). However, because of the increased risks of psychiatric adverse events, i.e., depressed mood disorders, anxiety, and suicidal ideation, rimonabant was withdrawn from the obesity treatment (42), and pharmaceutical companies discontinued clinical trials with tavanabant and ecopipam as antiobesity agents (40,41). Rimonabant positively influenced dyslipidemia and insulin resistance not only by decreasing the food intake in the brain but also by blocking peripheral CB1 receptors. CB1 blockade favorably affects lipogenesis in fat stores and liver, glucose uptake in skeletal muscle, and adiponectin secretion in adipose tissue.

Knowledge of peripheral targets of CB1 antagonists led to the development of a new CB1 antagonist, TM38837, which specifically acts in the peripheral tissues because of the lowered propensity to pass the blood-brain barrier (43). The phase I clinical trial with TM38837 was successfully completed in 2009 (J.M. van Gerver, unpublished results).

**COMBINATION DRUGS**—Approaches with two drug combinations of decreased doses were recommended to increase both the safety and efficacy of antiobesity treatment. However combinations of sibutramine and orlistat exhibited no advantages over the monotherapy with sibutramine alone (44,45). Combining fenfluramine and phentermine was aimed to achieve fewer adverse events and better appetite control (46). This drug combination, quite efficient in terms of weight loss and thus widely prescribed (over 18 million prescriptions in the U.S. in 1996!), was later shown to be associated with an increased risk of valvular heart disease (32). Phentermine interferes with the clearance of serotonin, and this way a combination of fenfluramine and phentermine may potentiate the untoward effects of circulating serotonin and result in valvular injury similar to that seen in patients with carcinoid syndrome (32).

Recently, several new drug combinations were investigated. The antidepressant bupropion, which acts as norepinephrine and dopamine reuptake inhibitor and melanocortin pathways stimulator, was combined with the opioid antagonist naltrexone, which antagonized proopiomelanocortin neurons inhibition by endogenous opioids. A sustained-release (SR) combination of naltrexone and bupropion was well tolerated and produced synergistic weight loss, which significantly exceeded that induced by placebo or by either drug alone (47,48). Naltrexone SR/bupropion SR (NB) combination therapy as an adjunct to behavior modification applied for 56 weeks induced significantly greater weight loss compared with behavior modification alone (9.3 ± 0.4% vs. 5.1 ± 0.6%, P < 0.001) (49). NB treatment was associated with improvements in body fat distribution, lipid profile, glucose homeostasis, and quality of life (49). The most frequent adverse event in response to NB treatment was nausea. NB combination treatment was not associated with increased depression and suicide attempts. Moreover, those using NB combination treatment exhibited fewer adverse psychiatric events than those using its components given separately (48,50). Transient increases in both sBP and dBP during the initial phase of NB treatment should however be carefully evaluated in future studies (48,50).

The addition of amylin (pramlintide) to leptin (metreleptin) restores leptin responsiveness in subjects with common obesity and after 12-months’ treatment results in significant weight loss (−11.5 kg), reduction in triglycerides (−8%), total cholesterol (−8%), fasting blood glucose (−4 mg/dL), insulinemia (−22%), and insulin resistance/homeostasis model assessment (−25%) (51). However, these combinations of antiobesity agents as well as other recently developed combinations—bupropion and zonisamide, phentermine and topiramate, pramlintide and sibutramine (52), pramlintide and phentermine (52)—require further long-term studies and a careful evaluation with regard to their efficacy and potential adverse events (53). Combination therapies using phentermine should consider that an administration of phentermine is recommended for a short-term period only.

**GUT HORMONES**—Several hormones of the gastrointestinal tract such as glucagon-like peptide 1 (GLP-1), cholecystokinin, amylin, pancreatic polypeptide, peptide YY (PYY3–36), oxyntomodulin (OXM), and ghrelin have been found to play important roles in energy balance regulation, and some have recently been investigated as pharmaceutical targets for obesity (54). The administration of physiological doses of gut-derived appetite-regulating agents is expected to be an efficient, specific, and thus a low side-effect approach in the treatment of obesity.

The GLP-1 is secreted from L-cells of the intestine in response to a meal. GLP-1 suppresses elevated glucagon secretion by pancreatic B-cells, enhances insulin secretion, decreases apoptosis in pancreatic B-cells, increases satiety in the brain, and delays gastric emptying. Postprandial GLP-1 secretion is reduced in diabetic patients compared with nondiabetic patients. GLP-1 receptor agonists such as liraglutide and exenatide represent a new treatment option for patients with diabetes, and especially those who are obese. A recent review of randomized controlled trials evaluated six trials with exenatide and six trials with liraglutide that were administered either alone or combined with oral antidiabetic drugs (55). Both drugs improved glycemic control, induced comparable weight losses, and reduced blood pressure (55). The most frequent side effects were transient mild nausea and minor hypoglycemia, which were less common with liraglutide.
than with exenatide (56). Antibodies developed with a lesser frequency in liraglutide-treated subjects than in those treated by exenatide, likely because of its greater structural similarity with human GLP-1 (97 vs. 52%). However, it is encouraging that the development of antibodies does not affect the drug efficacy. Combining GLP-1 analogs with metformin in obese patients with diabetes seems a reasonable approach, as both drugs possess the weight-lowering properties (57,58). The disadvantage of GLP-1 agonists is a need for parenteral administration—once daily with liraglutide and twice daily with exenatide. A recent study demonstrated that a long-term version of exenatide administered once weekly produced sustained glycemic control and weight loss over 52 weeks (59). Other recently developed GLP-1 agonists with prolonged half-lives such as taspoglutide and albiglutide will not affect the drug efficacy, and independent OXM receptors (GLP-1 receptor, glucagon receptor, and independent OXM receptor). Only preliminary data on energy intake, energy expenditure, and weight loss in humans after OXM and PYY3−36 have been available (61). The less frequent nausea after administration of OXM than after GLP-1 agonists encourages further clinical studies. To improve clinical usefulness of treatment, the breakdown-resistant analogs of OXM and intranasally administered analogs of PYY3−36 have been developed. A recently published study suggested that the anorectic effect of PYY3−36 and OXM can be additive (63). Coadministration of PYY3−36 and OXM intravenously reduced energy intake by 42.7% in comparison with saline control. This energy intake reduction after combined hormone administration was more pronounced than during infusions of either hormone alone.

**DURATION OF TREATMENT WITH ANTIOBESITY DRUGS**

Long-term administration of antiobesity drugs should be indicated according to the weight loss achieved in response to an initial 3-months’ therapy (64,65). A meta-analysis of sibutramine studies revealed that a weight loss of 4 kg at 3 months predicted weight loss >5% at 12 months (65). The drug administration should be discontinued in patients who do not respond to 3-months’ drug treatment. It has been demonstrated that intermittent treatment with some antiobesity drugs (phentermine, sibutramine) may be as effective as their continuous administration and may diminish both the side effects and costs (66,67). On the other hand, the long-term replacement of antiobesity drugs with placebo is followed by weight regain as demonstrated in the studies with sibutramine, lorcaserin, and rimonabant conducted over a 2-year period (5,37,39). It therefore should be considered that future drug treatment of obesity should be indicated for lifelong administration as in treating other complex diseases.

**CONCLUSIONS**—Currently available antiobesity drugs result in only modest weight loss accompanied by reductions of cardiometabolic health risks. Adverse events related to existing antiobesity drugs however, call for careful assessment of the risk/benefit profile in each new agent designed to treat obesity. Further studies evaluating the effect of antiobesity drugs on morbidity and mortality end points in appropriate target populations are needed. It is expected that the new compounds, which have recently been tested in clinical trials, will possess more advantages over the currently available agents both with regard to their efficacy and safety (68). However, it will be necessary for medical authorities to persuade not only physicians and patients but also the drug-regulating agencies (and their committees) that the drug treatment of obesity (de facto obesity) must evaluate antiobesity drugs just as they do those for other complex diseases (such as hypertension) and take into account their specific pathogenesis and character, age of a patient, and presence of comorbidities (69).

**ADDENDUM**—On October 8, 2010, the following statement was released by the Abbott Laboratories: “Abbott believes sibutramine has a positive risk/benefit profile in the approved patient population, but we will comply with the FDA’s [Food and Drug Administration’s] request and will voluntarily withdraw Meridia® (sibutramine) from the U.S. market.”

**Acknowledgments**—This study was partly supported by a grant from the Czech Ministry of Health (IGA 7800-4). V.H. participated as an investigator in the SCOUT Study supported by the Abbott Laboratories. No other potential conflicts of interest relevant to this article were reported.

**References**

1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. Geneva, World Health Org., 2000 (Tech. Rep. Ser., no. 894).

2. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary 1–3. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr 1998;68:899–917.

3. Tsigos C, Hainer V, Basdevant A, et al.; Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008;1:106–116.

4. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: what fits whom? Diabetes Care 2008;31(Suppl. 2):S269–S277.

5. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356:2119–2125.
6. Torgerson JS, Hauptman J, Boldrin MN, Sjöstrom L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–161
7. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194–1199
8. Neovius M, Johansson K, Rössner S. LS0114
9. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004;164:1395–1404
10. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev 2009;10:333–341
11. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999;23:1016–1024
12. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond) 2005;29:509–516
13. Johansson K, Sjöström J, Neovius K, Rosén S, Neovius M. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev 2010;11:777–791
14. Scheen A. Sibutramine on cardiovascular outcome. Diabetes Care 2011;34(Suppl. 2):S114–S119
15. James WPT, Caterson ID, Coutinho W, et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905–917
16. Tzamalos K, Krasse G, Tzoteas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009;5:441–452
17. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag 2007;3:817–821
18. Coutinho W. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arq Bras Endocrinol Metabol 2009;53:262–270
19. Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J Manag Care 2001;7:875–883
20. Hainer V, Kunsoeva M, Bellisle F, Hill M, Brunerova R, Wagenknecht M. Psychological and nutritional predictors of weight loss in obese women treated with sibutramine. Int J Obes (Lond) 2005;29:208–216
21. Elfhag K, Finer N, Rössner S. Who will lose weight on sibutramine or orlistat? Psychological correlates for treatment success. Diabetes Obes Metab 2008;10:498–505
22. Astrup A, Madsbad S, Brem L. Jensen T, Krousstrup JP, Larsen TM. Effect of teso- linsence on body weight, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906–1913
23. Sjödin A, Gasteyer C, Nielsen AL, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond) 2010;34:1634–1643
24. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibi- tor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007;31:494–499
25. Kopelman P, Groot GedeH, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerance of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring) 2010;18:108–115
26. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879–884
27. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008;70:537–556
28. Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005;115:3379–3386
29. Roubert P, Dubern B, Plas P, et al. Novel pharmacological MC4R agonists can ef- ficiently activate mutated MC4R from obese patient with impaired endogenous agonist response. J Endocrinol 2010;207:177–183
30. Guy-Grand B. Clinical studies with dexfenfluramine: from past to future. Obes Res 1995;3(Suppl. 4):491S–496S
31. Chow CC, Ko GT, Tsang LW, Yeung VT, Chan JC, Cockram CS. Dexfenfluramine in obese Chinese NIDDM patients: a placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. Diabetes Care 1997;20:1122–1127
32. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581–588
33. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703–1709
34. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological character- ization. J Pharmacol Exp Ther 2008;325:377–387
35. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR; APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009;17:494–503
36. Anderson CM, Smith SR, Sanchez M, Stubbe S, Shanahan WR. Lorcaserin treat- ment was associated with improvements in cardiovascular risk factors and weight loss in the BLOOM trial. Obesity (Silver Spring) 2009;17(Suppl. 2):S52
37. Smith SR, Weissman NJ, Anderson CM, Shanahan WR, the Behavioral Modifi- cation and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245–256
38. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rosser S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight re- duction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389–1397
39. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761–775
40. Aronne LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and effi- cacy of tariroban, a CB1R inverse ago- nist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) 2010;34:919–935
41. Astrup A, Greenway FL, Ling W, et al.; for the Ecopipam Obesity Study Group. Randomized controlled trials of the D1/D5 antago- nist ecopipam for weight loss in obese subjects. Obesity (Silver Spring) 2007;15:1717–1731
42. Christensen R, Kristensen PK, Barlets EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta- analysis of randomised trials. Lancet 2007;370:1706–1713
Antioesity drugs, efficiency, and safety

43. Receveur JM, Murray A, Linget JM, et al. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. Bioorg Med Chem Lett 2010; 20:453–457

44. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000;8:431–437

45. Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004;30:159–167

46. Weintraub M, Hasday JD, Mushlin Al, Lockwood DH. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984;144:1143–1148

47. Greenway FL, Whitehouse MJ, Guttaudatra M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17:30–39

48. Greenway FL, Fujikoa K, Pliikowski RA, et al.; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605

49. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110–120

50. Astrup A. Is cardiometabolic risk improved by weight-loss drugs? Lancet 2010;376: 567–568

51. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009;17:1736–1743

52. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring) 2010; 18:1739–1746

53. Klomoff DC, Greenway F. Drugs in the pipeline for the obesity market. J Diabetes Sci Tech 2008;2:913–918

54. Field BC, Chaudhri OB, Bloom SR. Obesity treatment: novel peripheral targets. Br J Clin Pharmacol 2009;68:830–843

55. White J. Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc (2003) 2009;49(Suppl. 1): S30–S40

56. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Lisproglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47

57. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 52 weeks. Diabetes Care 2009;32:1092–1100

58. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84–90

59. Buse JB, Drucker DJ, Taylor KL, et al.; DURATION-I Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255–1261

60. Elikind-Hirsch K, Marrionoueux O, Bhushan M, Vernon D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:2670–2678

61. Chaudhri OB, Wynne K, Bloom SR. Can gut hormones control appetite and prevent obesity? Diabetes Care 2008;31(Suppl. 2): S284–S289

62. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008;31:1816–1823

63. Field BC, Wren AM, Peters V, et al. PYY3–36 and oxyjntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010;59:1635–1639

64. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005;7: 699–708

65. Finer N, Ryan DH, Renn CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006;8: 206–213

66. Munro JF, MacCus AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968;1:352–354

67. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001;286:1331–1339

68. Astrup A. Drug management of obesity—efficacy versus safety. N Engl J Med 2010; 363:288–290

69. Dvorak RV, Sharma AM, Astrup A. Antiobesity drugs: to be or not to be? Obes Rev 2010;11:833–834